PCI Services, an integrated full service provider for the healthcare industry, is extending its current cryogenic storage facilities to its Rockford, Illinois operations in the latest in a series of expansion investments.

PCI’s investment, of which financial details were not disclosed, aims to reduce any potential logistical and technical challenges with the packaging, labelling, storage and distribution of drug products at cryogenic temperatures.

This latest move comes after PCI recently expanded its Bridgend site in the UK with a purpose-built and dedicated -40°C facility, as well as a broader cold chain capacity that increased site storage by over 400%.

The Rockford development combined with PCI’s expansion in Bridgend reflects the company’s investments at other UK and North American sites, supporting specialised services for clinical trials and business growth.

The US-based business provides a highly specialised network capability for supporting temperature-sensitive drug products including ultra-cold chain at temperatures down to -90°C and liquid nitrogen (N2) vapour phase storage at -196°C.

In a statement, the company said the investment echoes the changing needs of the pharmaceutical and biotech markets and offers critical dual site opportunities for clients’ cell banks and temperature-sensitive materials.

Brian Keesee, Executive Director, Clinical Services at PCI, highlighted, “The new facility is an example of our dedication to testing and validation the newest technologies and storage capabilities to ensure they are using the most effective methods for clients.”

PCI, headquartered in Pennsylvania, US, is specialised in dry ice and N2 shipping and storage systems with a global distribution network in handling, storage and distribution of temperature-sensitive products.